RYBREVANT + LAZCLUZE — Sales to customers (Note 9)
Johnson & Johnson RYBREVANT + LAZCLUZE — Sales to customers (Note 9) increased by 19.0% to $257.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 82.3%, from $141.00M to $257.00M. Over 2 years (FY 2023 to FY 2025), RYBREVANT + LAZCLUZE — Sales to customers (Note 9) shows an upward trend with a 180.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration and strong demand for the therapeutic product line, while a decrease may signal competitive pressure or loss of market share.
Detailed definition
This metric represents the total net revenue generated from the sale of specific oncology therapeutic products to extern...
Peer comparison
Comparable to revenue figures for specific high-growth oncology or specialty pharmaceutical product lines at peer biopharmaceutical companies.
jnj_segment_rybrevant_lazcluze_sales_to_customers_note_9Historical Data
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $23.25M | $23.25M | $23.25M | $23.25M | $47.00M | $69.00M | $89.00M | $122.00M | $141.00M | $179.00M | $198.00M | $216.00M | $257.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +102.2% | +46.8% | +29.0% | +37.1% | +15.6% | +27.0% | +10.6% | +9.1% | +19.0% |
| YoY Change | — | — | — | — | +102.2% | +196.8% | +282.8% | +424.7% | +200.0% | +159.4% | +122.5% | +77.0% | +82.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's rybrevant + lazcluze — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported rybrevant + lazcluze — sales to customers (note 9) of $257.00M in Q1 2026.
- How has Johnson & Johnson's rybrevant + lazcluze — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's rybrevant + lazcluze — sales to customers (note 9) increased by 82.3% year-over-year, from $141.00M to $257.00M.
- What is the long-term trend for Johnson & Johnson's rybrevant + lazcluze — sales to customers (note 9)?
- Over 2 years (2023 to 2025), Johnson & Johnson's rybrevant + lazcluze — sales to customers (note 9) has grown at a 180.9% compound annual growth rate (CAGR), from $93.00M to $734.00M.
- What does rybrevant + lazcluze — sales to customers (note 9) mean?
- The total revenue earned from selling specific oncology drugs to customers.